Oncology
Oncology & tumour immunology
Bispecific T-cell engagers and antibody–drug conjugates that convert cold tumours into immunologically visible ones, guided by circulating tumour DNA.
Clinical-stage biopharmaceuticals · Est. 2009
Precision medicine, engineered for the people who need it most.
Nine programmes in development across oncology, immunology, neurology, rare disease, cardio-metabolic and infectious disease — built on a single, modular drug platform and one standard of evidence.
9Programmes in development
6Therapeutic areas
480+Scientists & clinicians
14Countries in trial network
Product pipeline
Download pipeline overview (PDF)
Nine programmes. One standard of evidence.
From first-in-human to registrational filing — every NovaPharma programme is designed around a validated biomarker, a pre-registered endpoint and a manufacturing route we control end to end.
| Programme | Indication | Development phase | Next milestone |
|---|---|---|---|
| NOV-201 LeadBispecific antibody | Metastatic non-small cell lung cancer2nd line, PD-L1 positive | Phase III registration | Topline overall survivalExpected Q1 2027 |
| NOV-118Oral JAK1 inhibitor | Rheumatoid arthritisInadequate response to bDMARDs | Phase III registration | Regulatory submissionFDA & EMA, Q3 2027 |
| NOV-330Anti-tau monoclonal antibody | Early Alzheimer's diseasePre-symptomatic to mild | Phase II proof of concept | 18-month cognitive endpointExpected Q4 2026 |
| NOV-274AAV gene therapy | Duchenne muscular dystrophyAmbulatory, age 4–9 | Phase II dose expansion | Functional endpoint readoutExpected Q2 2027 |
| NOV-155Dual GLP-1 / GIP agonist | Type 2 diabetes & obesityOnce-weekly subcutaneous | Phase II dose ranging | 52-week weight & glycaemic dataExpected Q1 2027 |
| NOV-402mRNA vaccine | Respiratory syncytial virusAdults 60 years and over | Phase I dose escalation | Immunogenicity & safety dataExpected Q4 2026 |
| NOV-090siRNA therapeutic | Resistant hypertensionQuarterly dosing, hepatic target | Phase I first-in-human | Safety, PK & pharmacodynamicsExpected Q3 2026 |
| NOV-361Pan-KRAS small molecule | Advanced solid tumoursKRAS-mutant, basket design | Preclinical IND-enabling | IND submissionExpected Q2 2027 |
| NOV-508Inhaled antisense oligonucleotide | Idiopathic pulmonary fibrosisNebulised, lung-restricted | Preclinical lead optimisation | Development candidate selectionExpected Q4 2026 |
Showing 9 of 9 programmes · updated 24 September 2026
All programmes are investigational. Safety and efficacy have not been established, and no regulatory authority has approved these compounds for the indications shown.
Research areas
Where biology is still an open question.
We concentrate our effort where the mechanism is tractable and the patient need is unmet — six therapeutic areas, one shared discovery engine.
Oncology
Immunology
Immunology & inflammation
Selective intracellular signalling modulators designed to reset immune tolerance without the broad immunosuppression that patients pay for later.
Neurology
Neurology & CNS
Anti-tau and anti-synuclein biologics with brain-shuttle delivery, paired with digital cognitive endpoints measured in the patient's own home.
Rare disease
Rare disease & gene therapy
Single-dose AAV programmes for monogenic disease, with companion diagnostics developed in parallel so the right patient is found first time.
Cardio-metabolic
Cardio-metabolic disease
Incretin and siRNA medicines engineered for quarterly or monthly dosing, so adherence stops being the weakest link in the treatment chain.
Infectious disease
Infectious disease & vaccines
Thermostable mRNA vaccines formulated to survive the last mile — no cold chain, no missed dose, designed for outbreak response in weeks.
Company values
How we work when nobody is watching the data.
NovaPharma was founded by clinicians who had watched good molecules fail for avoidable reasons. Our four values are operational commitments, not poster copy — each one maps to a rule in our SOPs.
“We do not have a speed problem in this industry. We have an evidence problem. Fix the evidence and the timeline fixes itself.”
Dr. Adrian Kessler · Co-founder & Chief Executive Officer
01
Patients before programmes
Every design decision starts with the person who will take the medicine — dosing burden, travel, and what a bad day actually costs them.
02
Evidence over enthusiasm
Our protocols and analysis plans are pre-registered before first patient in. We publish methods, not just outcomes.
03
Open by default
Assays, tooling and negative results are shared with our academic partners. Science that stays in a drawer is science wasted.
04
Speed with integrity
We compress timelines through better engineering — automation, adaptive design, real-world data — never through shortcuts.
Leadership
Board & governance
The people accountable for the pipeline.
An executive team that has taken 40+ molecules from candidate selection to approval — and knows exactly how each one could have gone wrong.
PhD Molecular Biology. 22 years in biopharma; previously led global oncology commercial strategy at a top-10 pharmaceutical company.
Dr. Adrian Kessler
Co-founder & Chief Executive Officer
Led 3 oncology launches across 30 markets.
Former regulatory reviewer turned sponsor. Has designed or overseen more than 30 registrational trials across four continents.
Dr. Priya Raman
Chief Medical Officer
30+ registrational trials · ex-FDA reviewer.
Architect of the NOVA-DELIVERY™ platform and the company's biomarker-first discovery process. 90+ peer-reviewed publications.
Dr. Sofia Lindqvist
Chief Scientific Officer
Inventor on 41 platform patents.
18 years in life-science finance. Has raised over $2.1 billion across four public offerings and two private rounds.
Dr. Marcus Rehn
Chief Financial Officer
4 IPOs · $2.1B raised for science-led teams.
Investor relations
Building a durable pipeline — and durable value.
NovaPharma is listed on the Nasdaq Global Select Market under the ticker NVPH. Our capital plan funds all nine programmes through their next major inflection point without further equity issuance.
$1.24BCash & equivalents
Into 2030Funded runway
$612MFY25 R&D investment
1,480Employees worldwide
IR enquiries — ir@novapharma.com · +65 6812 4400 · Transfer agent: Equiniti Trust
Newsroom
All news & releases
Latest from the labs and the boardroom.
NOV-201 clears interim futility analysis in second-line NSCLC
The independent data monitoring committee recommended the Phase III trial continue without modification after reviewing the pre-specified interim analysis.
Read release
NovaPharma opens 40,000 sq ft automated biologics facility in Singapore
The GMP site adds 12,000 litres of single-use bioreactor capacity and brings clinical supply for six programmes fully in-house.
Read release
EMA grants PRIority Medicines status to NOV-118 for rheumatoid arthritis
PRIME designation provides enhanced scientific advice and accelerated assessment for the oral JAK1 programme ahead of its Phase III readout.
Read release